NCT00322712

Brief Summary

Chart Review of patients with pancreatic cancer treated with combination of irinotecan, oxaliplatin and cetuximab.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Sep 2006

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 5, 2006

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 8, 2006

Completed
4 months until next milestone

Study Start

First participant enrolled

September 1, 2006

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2006

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2007

Completed
8.2 years until next milestone

Results Posted

Study results publicly available

March 4, 2015

Completed
Last Updated

February 5, 2024

Status Verified

January 1, 2024

Enrollment Period

3 months

First QC Date

May 5, 2006

Results QC Date

February 11, 2015

Last Update Submit

January 9, 2024

Conditions

Pancreatic Cancer

Outcome Measures

Primary Outcomes (1)

  • Time to Death

    Length of survival of patients treated with a combination of Oxaliplatin 60mg/m2, Irinotecan 90mg/m2, and Cetuximab 250 mg/m2 delivered every other week.

    From date of treatment until time of death

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with unresectable/metastatic pancreatic cancer treated in the UNM Cancer Research and Treatment Center.

You may qualify if:

  • Patients with unresectable/metastatic pancreatic cancer treated in the UNM Cancer Research and Treatment Center.

You may not qualify if:

  • Not specified.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of New Mexico

Albuquerque, New Mexico, 87131, United States

Location

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Results Point of Contact

Title
Dr. Fa Chyi Lee
Organization
University of New Mexico
flee@salud.unm.edu
505-925-0405

Study Officials

  • Fa-Chyi Lee, MD

    University of New Mexico

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 5, 2006

First Posted

May 8, 2006

Study Start

September 1, 2006

Primary Completion

December 1, 2006

Study Completion

January 1, 2007

Last Updated

February 5, 2024

Results First Posted

March 4, 2015

Record last verified: 2024-01

Locations

US(1)